Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders for Inhibikase Therapeutics, Inc., held on June 26, 2026, in a virtual-only format. The filing details the outcomes of six proposals submitted to stockholders, including director elections, auditor ratification, corporate governance amendments, and equity plan modifications.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
- Director Elections: Arvind Kush and Dennis Berman were elected as Class III directors to serve until the 2029 annual meeting.
- Arvind Kush: 70,338,595 votes for; 12,770,121 votes withheld.
- Dennis Berman: 64,127,395 votes for; 18,981,321 votes withheld.
- Equity Plan Amendment: Stockholders approved an amendment to the 2020 Equity Incentive Plan to increase the authorized number of shares reserved for issuance by 3,000,000 shares.
- Votes For: 60,795,802
- Votes Against: 22,135,512
- Corporate Governance: Stockholders approved an amendment to the Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law.
- Votes For: 82,321,246
- Votes Against: 779,416
- Auditor Ratification: CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 106,910,712
- Votes Against: 96,428
- Executive Compensation:
- Advisory vote on compensation (Say-on-Pay) was approved with 61,237,304 votes for and 21,648,671 against.
- Advisory vote on frequency of future compensation votes resulted in a decision to hold such votes annually (77,456,671 votes for 1-year frequency).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, or specific risk factors. The document serves as a record of the Annual Meeting proceedings and the effective filing of the Certificate of Amendment with the Delaware Secretary of State.
Investor Verification Checklist
- Verify the impact of the 3,000,000 share increase in the 2020 Equity Incentive Plan on potential future dilution.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific scope of officer liability limitations.
- Confirm the tenure and background of newly elected directors Arvind Kush and Dennis Berman.
- Monitor the company's upcoming fiscal year-end financial reports for the fiscal year ending December 31, 2026, as audited by CohnReznick LLP.